ClinicalTrials.gg
Not yet recruitingNCT07798089Updated Sep 1, 2026

Propofol-Dexmedetomine Adjunction in Balanced Anesthesia for Minimally Invasive Cardiac Valve Surgery :Effect on Anesthetic Consumption ,Perioperative Outcomes,and Early Recovery

A Phase 1/2 interventional study of Propofol (Astra-Zeneca) and propofol and dexmetomidine in Balanced Anesthesia for Minimally Invasive Cardiac Valve Surgery, sponsored by Kafrelsheikh University. Not yet recruiting. Open to participants aged 25 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Kafrelsheikh University · Phase 1/2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
25 Years to 60 Years
Sex
All
01

Study summary

Propofol-Dexmedetomidine Adjunction in Balanced Anesthesia for Minimally Invasive Cardiac Valve Surgery: Effects on Anesthetic Consumption, perioperative outcomes, and Early Recovery

Read the detailed description

This prospective, randomized, double-blind study was conducted to evaluate the effect of dexmedetomidine as an adjunct to propofol-based anesthesia in patients undergoing minimally invasive cardiac valve surgery. Patients were randomly allocated to receive either dexmedetomidine or placebo in addition to standard propofol-based anesthesia. The primary outcome was total propofol consumption during surgery. Secondary outcomes included intraoperative hemodynamic parameters, anesthetic and recovery characteristics, and postoperative outcomes.

02

Conditions studied

  • Balanced Anesthesia for Minimally Invasive Cardiac Valve Surgery

Keywords

  • propofol , Dexmedetomidine ,Minimally Invasive Cardiac Valve Surgery
03

In context

Lead sponsor

Kafrelsheikh University is the lead sponsor of 301 studies on the registry; 119 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. patients belonging to (ASA) class I or II
  2. patients scheduled for minimally invasive cardiac valve surgery.

Exclusion criteria

Exclusion Criteria:

  1. patient more than 60 years
  2. patients having neurological/psychological disorders,
  3. patient having severe systemic disorders (renal/hepatic dysfunction and severe respiratory disorder),
  4. patient with history of allergy to the study drugs,
  5. patient with \< 40%,
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Propofol group (Group P) (control group)

    Drug: Propofol (Astra-Zeneca)

  • Active comparator
    Propofol dexmedetomidine group (Group PD)

    Drug: propofol and dexmetomidine

Interventions

  • Thirty patients will receive a continuous infusion of propofol at a rate of 2 mg/kg/h and 50 cc 0.9% sodium chloride solution infused at a rate of 0.4 µg/kg/h (used as a placebo).

  • Drugpropofol and dexmetomidine

    patients will receive a continuous infusion of propofol at a rate of 2 mg/kg/h in addition to dexmedetomidine at a rate of 0.4 µg/kg/h.

06

What researchers measure

Primary outcomes

  1. total intraoperative isoflurane consumption between propofol dexmedetomidine anesthesia and propofol anesthesia alone under entropy-guided anesthesia

    Total intraoperative isoflurane consumption Description: The total amount of isoflurane consumed during anesthesia will be compared between patients receiving propofol-dexmedetomidine anesthesia and those receiving propofol anesthesia alone under entropy-guided anesthesia. Isoflurane consumption will be assessed from induction of anesthesia until discontinuation of anesthesia and measured as the total volume consumed. (ML\\MIN)

    Time frame: Time Frame: From induction of anesthesia until discontinuation of anesthesia; total isoflurane consumption will be recorded at the end of surgery.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Dec 2026, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2026
First posted
Sep 1, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Dec 1, 2026
CompletionEst.
Jan 15, 2027
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07798089
Responsible party
Donia Hany Saad (Lecturer of Anesthesiology and Surgical Intensive Care, Kafrelsheikh University) — Principal investigator
First posted
Sep 1, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
Jan 15, 2027 (estimated)
Last update
Sep 1, 2026

Study contacts

Donia Hany Hany, MD
Contact
doniahany1788@gmail.com
01014498540

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion